USAntibiotics's plant in Tennessee is one of the last plants in the United States that makes amoxicillin, the crucial antibiotic that has been in shortage in some forms since 2022. But the plant isn’t breaking even, financially. WSJ’s Liz Essley Whyte reports on why it is so hard for American-made generic drugs manufacturers to survive.
Further Listening:
- Will Florida’s Plan to Get Cheap Drugs From Canada Work?
- Trillion Dollar Shot
Further Reading:
- Drug Shortages in America Reach a Record High
- Drug Shortages Trigger FTC Probe
Learn more about your ad choices. Visit megaphone.fm/adchoices
Trillion Dollar Shot, Episode 2: Bank Breakers
The Race to Save an Iconic Train From Falling Into the Ocean
The Life of One of Wall Street’s Greatest Investors
Live from Seattle: A Weird Economy + Election = ??
North Korea’s Propaganda Mastermind
How FTX Found Billions to Repay Customers
Trillion Dollar Shot, Episode 1: Birth of a Blockbuster
A Lawyer Says He Doesn't Need Help for Psychosis. His Family Disagrees.
Can Chinese Customers Rescue Starbucks?
The Suitcases Full of Cash Flowing Through Airports
Why Is Tesla Pulling Back on EV Charging?
The 20,000 Steps to a Walmart Manager's Six-Figure Salary
Guns and Death Threats in Canada’s Baby-Eel Fisheries
The NBA's Media Rights Are Up for Grabs. Billions Are at Stake.
Mayhem at Paramount as Merger Looms
Trump Allies Draft Plans to Rein in the Fed
Amazon’s Secret Operation to Gather Intel on Rivals
JP Morgan CEO Jamie Dimon on What's Next for the Economy
Pro-Palestinian Protests and Arrests at U.S. Colleges
How Gambling Scandals Are Rocking Sports Leagues
Create your
podcast in
minutes
It is Free
WSJ What’s News
WSJ Your Money Briefing
WSJ Opinion: Potomac Watch
The Daily
Today, Explained